Melanotan-1 Acetate 10mg Review

Editor's Verdict

Melanotan-1 Acetate 10mg from Apollo Peptide Sciences sits at an interesting intersection of well-characterized pharmacology and genuinely limited commercial alternatives. Unlike many research peptides whose mechanistic profiles rest on rodent data alone, Melanotan-1 (afamelanotide, [Nle4,D-Phe7]-alpha-MSH) has accumulated a respectable clinical trial record through its development as the photoprotective implant Scenesse for erythropoietic protoporphyria (EPP). 1 That clinical pedigree does not transform a research-grade lyophilized vial into a licensed medicine, but it does mean investigators can benchmark their in vitro and ex vivo findings against a body of human pharmacokinetic and pharmacodynamic data that is essentially unique among cosmetic-category research peptides.

The 10 mg lyophilized vial format is well-matched to laboratory reconstitution protocols. At the literature-reported research concentrations used in cell-culture studies (typically 1-100 nM), a single 10 mg vial can generate large working stock volumes, making per-experiment cost low. The $50.00 price point is competitive relative to catalog offerings from other research suppliers, though price alone is a weak proxy for quality; purity verification through independent mass spectrometry and HPLC remains the only defensible quality check, a topic covered at length in the purity section below.

The compound's selectivity profile distinguishes it sharply from Melanotan-II, a point the literature reiterates repeatedly. 2 MC1R-selective agonism drives the eumelanin biosynthesis pathway and downstream photoprotective signaling without the broad melanocortin receptor engagement (MC3R, MC4R) that gives Melanotan-II its penile erection, appetite suppression, and central side-effect signature. For researchers specifically interested in melanocyte biology, UV-damage protection mechanisms, Nrf2 pathway activation, or NF-kB-mediated inflammation in skin cells, Melanotan-1 is the more relevant tool.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical development

The melanocyte-stimulating hormone (MSH) family has been studied since the 1950s, when extraction and bioassay work confirmed that pituitary-derived peptides could darken amphibian skin. The endogenous mammalian ligand, alpha-MSH, is a 13-amino-acid peptide (His-Phe-Arg-Trp at positions 6-9 constitute the core pharmacophore) cleaved post-translationally from proopiomelanocortin (POMC). Its short in vivo half-life, estimated in minutes, and modest receptor affinity limited early therapeutic ambitions. 3

The critical structural optimization work was performed at the University of Arizona by Victor Hruby and colleagues in the 1980s. Their goal was to create a "superpotent" analog resistant to peptidase cleavage while retaining or enhancing receptor activation. Two substitutions proved transformative: replacement of methionine at position 4 with norleucine (Nle) eliminated the oxidation-labile thioether side chain, and substitution of L-phenylalanine at position 7 with its D-enantiomer (D-Phe) introduced conformational constraint that increased receptor binding affinity and slowed enzymatic degradation substantially. 4 N-terminal acetylation (Ac) and C-terminal amidation (-NH2) were retained from the endogenous peptide. The resulting [Nle4,D-Phe7]-alpha-MSH, patented and initially called Melanotan-I in the research literature, is the compound now generically known as afamelanotide and sold under the brand name Scenesse (Clinuvel Pharmaceuticals) as a 16 mg subcutaneous biodegradable implant. 5

Sequence and structural identity

The full sequence is Ac-Ser1-Tyr2-Ser3-Nle4-Glu5-His6-D-Phe7-Arg8-Trp9-Gly10-Lys11-Pro12-Val13-NH2. This is a linear (non-cyclic) tridecapeptide, which contrasts with Melanotan-II's cyclic heptapeptide architecture. The molecular formula C78H111N21O19 gives a monoisotopic mass of approximately 1645.84 Da; the average molecular weight of the acetate salt form used in research vials is 1646.85 Da. 6

The D-Phe7 substitution is pharmacologically decisive. D-amino acids resist chymotrypsin and most serine proteases that readily cleave L-Phe bonds, explaining much of the enhanced in vivo stability. Circular dichroism spectroscopy studies suggest D-Phe7 induces a type-II beta-turn around the His-Phe-Arg-Trp pharmacophore, a conformation that mimics the receptor-bound state of native alpha-MSH and partly explains the higher receptor affinity. 4 The Nle4 substitution provides an isosteric but oxidation-resistant replacement for Met4; without it, the peptide would be susceptible to reactive oxygen species encountered in inflammatory tissue environments, precisely the conditions of interest to many researchers.

Nomenclature clarity

Several names circulate in the literature for this compound: Melanotan-1, MT-1, afamelanotide, and [Nle4,D-Phe7]-alpha-MSH are all used interchangeably and refer to the same tridecapeptide. "Melanotan-II" (MT-II) refers to an entirely different, cyclic heptapeptide analog (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) with a different receptor selectivity profile. The two compounds are frequently confused in non-specialist commentary, but they are structurally and pharmacologically distinct. 2

Mechanism of Action

Receptor binding and selectivity

Afamelanotide is a full agonist at the melanocortin-1 receptor (MC1R), a Gs protein-coupled receptor encoded by the MC1R gene on chromosome 16q24. 7 MC1R is expressed at highest density on melanocytes, keratinocytes, and dermal fibroblasts, but receptor transcripts have also been documented in immune cells (monocytes, macrophages, dendritic cells), endothelial cells, renal podocytes, neurons, and skeletal muscle. 8 Radioligand binding studies using radiolabeled NDP-alpha-MSH (a close structural congener) indicate high-affinity binding to MC1R with Ki values in the low nanomolar to sub-nanomolar range; afamelanotide's affinity at MC1R is estimated to be at least 100-fold greater than that of the endogenous alpha-MSH ligand.

At the other melanocortin receptor subtypes (MC2R through MC5R), afamelanotide's affinity is substantially lower. MC2R (the ACTH receptor, adrenal) shows essentially no binding. MC3R and MC4R, the central nervous system subtypes implicated in energy homeostasis and sexual function, show measurable but significantly weaker binding relative to MC1R. 2 This selectivity profile is the primary reason that afamelanotide lacks the erection-inducing and appetite-suppressing properties of Melanotan-II, which engages MC3R and MC4R with higher efficacy. For researchers specifically interrogating MC1R biology, this selectivity is a significant experimental advantage.

cAMP / PKA / MITF signaling cascade

After afamelanotide binds MC1R, the associated Gs protein dissociates and activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP). 9 Elevated cAMP activates protein kinase A (PKA), which phosphorylates the cAMP response element-binding protein (CREB) at Ser133. Phospho-CREB then acts as a transcription factor at cAMP response elements (CRE) within the promoter of the microphthalmia-associated transcription factor gene (MITF). MITF upregulation drives expression of the rate-limiting enzymes of the eumelanin biosynthetic pathway: tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and DCT (TYRP2). 9

The biochemical result is an increase in eumelanin content within melanosomes, followed by melanosome transfer to keratinocytes via dendritic extensions. Eumelanin (as opposed to the red-yellow pheomelanin produced via the beta-defensin 3/ASIP axis) acts as a broad-spectrum UV absorber and free radical scavenger, reducing UV-induced DNA photoproducts in the epidermis. 10 This is the molecular basis of the photoprotective effect documented in EPP clinical trials.

Nrf2 pathway and oxidative stress

Beyond the cAMP/MITF axis, MC1R activation in keratinocytes and melanocytes has been shown to upregulate nuclear factor erythroid 2-related factor 2 (Nrf2). 11 Nrf2 is a master regulator of the antioxidant response, translocating to the nucleus where it drives expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase (GCL), and other cytoprotective enzymes. Research in human keratinocyte cell lines showed that nanomolar concentrations of afamelanotide increase Nrf2 nuclear translocation and reduce UV-induced 8-oxo-deoxyguanosine formation independently of melanin content changes, suggesting a direct cytoprotective mechanism separable from pigmentation. 11

This pathway is particularly relevant for research into non-melanocyte tissues. Studies in renal podocytes, where MC1R is expressed, demonstrated that MC1R agonism attenuates oxidative stress induced by advanced glycation end-products, partly through Nrf2/HO-1 induction. 12 The breadth of Nrf2-related findings suggests that afamelanotide's research utility extends beyond pigmentation biology into broader cytoprotection research.

NF-kB inhibition and anti-inflammatory signaling

Separate from cAMP signaling, MC1R activation attenuates NF-kB activity in several immune and epithelial cell types. 13 NF-kB is the central transcription factor governing pro-inflammatory cytokine production (IL-1beta, TNF-alpha, IL-6, IL-8). In human dermal fibroblasts stimulated with lipopolysaccharide (LPS), afamelanotide reduced NF-kB nuclear translocation and suppressed IL-6 and TNF-alpha secretion. The mechanism is thought to involve PKA-mediated phosphorylation of IkB kinase (IKK), which prevents IkB degradation and thus NF-kB release. 13

This anti-inflammatory signaling component partly explains why EPP patients on afamelanotide report reductions in photo-provoked inflammatory pain beyond what pigmentation changes alone could explain, and it opens potential applications in inflammatory skin disease research models.

Tissue distribution of MC1R

In terms of tissue-level distribution, MC1R expression is not limited to skin. Documented expression sites include the frontal cortex, locus coeruleus, hypothalamus, adrenal medulla, ovary, testis, lung, skeletal muscle, immune cells, and vascular endothelium. 8 However, in the context of systemically administered afamelanotide at literature-reported research doses, the functional read-outs in non-skin tissues are modest compared with the robust pigmentary and photoprotective responses. The reason is almost certainly differential receptor density; melanocytes express MC1R at extraordinarily high surface density relative to most other cell types, meaning the compound's pharmacological effects are skin-dominant at the whole-organism level even though the receptor itself is broadly distributed.

What the Research Says

Fitzgerald et al. (1996): Phase I/II pharmacokinetics and tanning response

One of the foundational human studies of afamelanotide was published in 1996 by Fitzgerald and colleagues, who administered escalating single subcutaneous doses to healthy volunteers. 14 The study design used bolus SC injections in doses ranging from 0.16 mg/kg to 0.32 mg/kg, with blood sampling over 24 hours and colorimetric skin measurements (Mexameter) at multiple time points over 28 days. The study enrolled 28 participants and was designed as a dose-escalation safety and pharmacokinetic assessment rather than a powered efficacy trial.

Key pharmacokinetic findings from this study established the canonical human PK parameters for afamelanotide as a bolus SC injection: time to maximum plasma concentration (Tmax) of approximately 0.5-1 hour, a biphasic elimination with a distribution half-life of roughly 30 minutes and terminal half-life of 0.8-1.7 hours, and absolute bioavailability of approximately 100% relative to intravenous dosing (indicating complete SC absorption). Oral bioavailability was undetectable, consistent with the peptide's susceptibility to gastrointestinal peptidases despite its increased stability relative to native alpha-MSH. 14

The pharmacodynamic findings were perhaps more striking: increased skin pigmentation (L*, a*, b* colorimetric changes) was measurable at all doses tested, with onset within 5-7 days and persistence for 4 or more weeks after the single injection. The prolonged pigmentary effect relative to the short plasma half-life suggests a mechanism based on persistent MITF-driven transcriptional changes and melanosome maturation cycles rather than continuous receptor occupancy. Side effects at these doses included transient facial flushing, nausea at the higher dose level, and sporadic spontaneous penile erections in male participants, which the authors noted were unexpected given afamelanotide's nominal MC1R selectivity. Whether this reflected off-target MC4R engagement at high plasma concentrations or secondary paracrine mechanisms was not resolved in this study. A key limitation is the small sample size and lack of placebo control in the early cohorts.

Minder et al. (2009): Randomized controlled trial in erythropoietic protoporphyria

The Minder et al. 2009 publication in the New England Journal of Medicine represented the first rigorously controlled phase III evaluation of afamelanotide in EPP, a condition where absence of functional ferrochelatase causes porphyrin accumulation in the skin and severely painful phototoxic reactions to sunlight. 1 The trial enrolled 93 adult EPP patients across European centers, randomizing them 2:1 to a single 16 mg biodegradable SC implant (PLGA matrix) or matching placebo, with the primary endpoint being total direct sunlight exposure time without pain over 180 days post-implant.

The treatment group achieved a median of 69.4 hours of pain-free sunlight exposure versus 40.8 hours in the placebo group (p = 0.005), a clinically meaningful improvement. The implant format releases afamelanotide over approximately 60 days, maintaining sustained low plasma concentrations that drive a prolonged pigmentary and photoprotective response very different from the transient PK profile seen with bolus SC injection. Secondary endpoints including quality-of-life scores (DLQI) and patient-reported anxiety about sun exposure also favored treatment. Adverse events were predominantly mild: transient implant-site reactions, nausea in 8% of treated participants, headache, and hyperpigmentation were the most frequent. No serious cardiovascular, hepatic, or hematological events attributable to drug were reported.

The study has several important limitations. It was not powered to evaluate long-term safety signals such as melanoma. EPP patients are selected for severe MC1R-related photosensitivity, meaning their receptor biology may not be representative of investigators working with normal-pigmentation cell lines. The 16 mg implant format is pharmacokinetically distinct from the 10 mg lyophilized vial used in solution-phase laboratory research, and direct comparison of in vivo implant data with in vitro bolus administration studies requires careful consideration of Cmax versus AUC-driven effects.

Lim et al. (2015): Long-term safety analysis

A critical safety question for any compound that chronically activates MC1R is melanoma risk, given that MC1R is the receptor through which ultraviolet radiation normally drives melanocytic proliferation. Lim and colleagues conducted a systematic pooled analysis of safety data from afamelanotide clinical trials involving more than 200 patients receiving repeat-dose 16 mg implants over up to 5 years, supplemented by post-marketing pharmacovigilance data. 5 The analysis specifically examined pigmented lesion counts, nevus morphology changes, and melanoma incidence.

No cases of melanoma attributable to afamelanotide treatment were identified across the combined dataset. Quantitative dermoscopy monitoring showed stable nevus morphology in the vast majority of participants, with a subset showing minor increases in nevus size considered within normal variation. The authors noted that this finding is mechanistically plausible: afamelanotide drives eumelanin synthesis, which is photoprotective and reduces UV-induced DNA mutations, rather than the pheomelanin pathway that generates reactive oxygen species and is more closely linked to UV-independent melanocytic DNA damage. 5

The primary limitation of this analysis is the sample size (approximately 200 patients) and maximum 5-year follow-up, which are insufficient to detect a doubling of an event rate as rare as melanoma in the general population (approximately 20 cases per 100,000 per year). A true melanoma safety signal would require a cohort of thousands followed for decades. Researchers using afamelanotide in cell models where melanocytic proliferation is an endpoint should therefore design assays that directly measure proliferative markers (Ki-67, PCNA) rather than inferring safety from clinical trial data.

Haylett et al. (2011): Photoprotection mechanism in vitro

Haylett and colleagues used a human melanocyte and keratinocyte co-culture model to dissect the cellular mechanisms of afamelanotide-mediated photoprotection. 10 They treated co-cultures with 10 nM and 100 nM afamelanotide for 72 hours before UV-B irradiation and measured cyclobutane pyrimidine dimer (CPD) formation, p53 induction (a UV damage marker), and caspase-3/7 activation as indices of apoptosis. The compound significantly reduced CPD formation at both concentrations, with 100 nM providing approximately 35% CPD reduction relative to vehicle-treated controls (p < 0.01). Caspase activation was also reduced in a dose-dependent manner.

This study is valuable to laboratory researchers because it establishes a dose-response relationship at pharmacologically accessible concentrations in a relevant human cell model, and it uses validated molecular endpoints (CPD immunofluorescence, western blot p53) that are reproducible across labs. The authors also performed eumelanin quantification to confirm that the CPD reduction correlated with melanin content increases, though the relationship was not perfectly linear, supporting the idea that Nrf2-mediated DNA repair enhancement contributes to photoprotection alongside the physical UV-shielding effect of increased melanin. A limitation is the use of a single UV-B dose (20 mJ/cm2) that may not capture concentration-response behavior across the full range of UV exposures relevant to different research questions.

Collier et al. (2014): Nrf2 pathway activation in keratinocytes

Collier et al. published a mechanistic study examining whether afamelanotide could activate Nrf2 in human keratinocytes lacking functional MC1R, testing the hypothesis that signaling might be receptor-independent at higher concentrations. 11 Using wild-type and MC1R-knockdown HaCaT keratinocyte lines, they found that 10-100 nM afamelanotide robustly induced Nrf2 nuclear translocation and HO-1 protein expression in wild-type cells but not in MC1R knockdown cells, confirming that the effect was receptor-dependent. This definitively places Nrf2 activation downstream of MC1R/cAMP signaling rather than as a direct chemical effect of the peptide.

The study also measured NQO1 activity and glutathione synthesis (via GCL induction) as functional readouts of the Nrf2 response, providing a multi-endpoint confirmation. Interestingly, the authors tested the MC1R antagonist agouti-signaling protein (ASIP), which completely blocked afamelanotide-induced Nrf2 activation, while a PKA inhibitor (H-89) also abrogated the effect, situating the Nrf2 response firmly within the canonical cAMP/PKA signaling arm downstream of MC1R. Limitations include the use of an immortalized cell line (HaCaT) rather than primary human keratinocytes, a distinction that can affect absolute magnitude of signaling responses.

Kadekaro et al. (2012): DNA repair gene regulation

Kadekaro and colleagues extended the mechanistic picture further by examining whether MC1R activation by afamelanotide influenced not just antioxidant defenses but also DNA repair gene expression. 15 In primary human melanocyte cultures, treatment with 10 nM afamelanotide for 48 hours before UV-B irradiation significantly upregulated XPC and XPE expression (nucleotide excision repair genes), PCNA (involved in DNA synthesis and repair), and reduced the half-life of CPD lesions after UV exposure. The authors interpreted this as evidence that MC1R agonism primes the nucleotide excision repair (NER) pathway, providing a mechanistic rationale for the disproportionate reduction in UV-induced mutation frequency relative to the increase in melanin content alone.

This work is particularly relevant for researchers designing photo-carcinogenesis models. The finding that NER pathway upregulation occurs at concentrations as low as 10 nM allows experimenters to test specific hypotheses about DNA repair biology using pharmacological MC1R activation without needing to achieve supraphysiological peptide concentrations. The study's primary limitation is that it does not examine the same endpoints in keratinocytes or fibroblasts, leaving open the question of whether NER upregulation is melanocyte-specific or extends to other UV-exposed skin cell types.

Pharmacokinetics

The pharmacokinetic behavior of afamelanotide depends strongly on formulation and route of administration. The three clinically or experimentally relevant scenarios are bolus subcutaneous injection (used in early phase I/II trials and by some preclinical researchers), the 16 mg PLGA biodegradable implant (the approved clinical form), and in vitro direct addition to cell culture media. Only the first two have published human PK data; in vitro media concentrations are dictated by the experimenter's pipetting.

For bolus SC injection, the key parameters from Fitzgerald et al. are: Tmax approximately 0.5-1 hour, Cmax dose-proportional across the studied range, volume of distribution approximately 0.3-0.4 L/kg (suggesting limited tissue accumulation beyond extracellular fluid), terminal half-life 0.8-1.7 hours, and no detectable metabolites with known pharmacological activity. 14 Metabolism proceeds primarily via peptidase cleavage, with rapid degradation in plasma and at the SC injection site. Renal clearance of intact peptide is minimal; the principal elimination route is proteolytic inactivation.

For the implant formulation, PLGA biodegrades over approximately 60 days, releasing afamelanotide at rates modeled to produce sustained plasma concentrations far below the Cmax achieved with bolus injection but sufficient to drive persistent MC1R engagement. This explains why the implant's pharmacodynamic effects (pigmentation, photoprotection) persist for months after implant biodegradation is complete: the slow, prolonged receptor activation drives sustained MITF-target gene expression changes that outlast the peptide itself.

The disconnect between short plasma half-life and prolonged pharmacodynamic effects deserves particular attention for researchers designing in vitro time-course experiments. A single treatment of melanocytes with afamelanotide followed by washout can produce MITF-target gene upregulation for 48-72 hours after peptide removal, suggesting that transcriptional imprinting via CREB phosphorylation persists beyond receptor occupancy. Researchers planning time-course studies should therefore include appropriate washout arms to distinguish sustained signaling from receptor re-engagement by residual peptide.

Purity and Verification

What a certificate of analysis (CoA) should show

Any research-grade afamelanotide vial should be accompanied by a certificate of analysis (CoA) specifying at minimum: identity confirmation by mass spectrometry, purity by reversed-phase HPLC (area under the curve method), and net peptide content (total peptide weight after correcting for water, acetate, and residual solvent content). A stated purity of greater than 98% by HPLC is the accepted research-grade threshold. Net peptide content is a separate and important number: a vial labeled "10 mg" that is only 75% net peptide by weight (with the remainder being acetic acid, water, and excipients) contains only 7.5 mg of actual afamelanotide. 16

Reputable suppliers provide CoAs with a batch number, synthesis date, and identified retention time for the HPLC trace. The mass spectrum should show a molecular ion consistent with the average molecular weight of 1646.85 Da (or its acetate-adjusted equivalent), with additional peaks corresponding to multiply charged species [M+2H]2+ at approximately 824 Da and [M+3H]3+ at approximately 549 Da, all characteristic of this molecular mass by electrospray ionization. 16

Independent verification approaches

For researchers who cannot take a supplier CoA at face value, several independent verification approaches are practical. Liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) performed by an independent analytical laboratory provides both sequence confirmation and purity. The cost per sample at academic core facilities is typically modest ($50-150), and the experiment takes 1-2 business days, making it a practical pre-experiment quality check.

For simpler purity screening, analytical HPLC with a C18 reversed-phase column and acetonitrile/water/TFA gradient can confirm that no significant peaks other than the expected principal peak are present. Comparing retention time and peak shape against a characterized reference standard (available from sources such as Sigma-Aldrich or the American Peptide Company at certified reference grade) provides additional confidence. For researchers with access to nuclear magnetic resonance (NMR), 1H NMR can confirm the presence of characteristic residues (Trp indole NH at approximately 10.2 ppm, Arg guanidinium protons at approximately 7.2 ppm) and detect gross impurities, though NMR sensitivity is lower than LC-MS for trace contaminants.

Anti-doping laboratories have developed validated LC-MS/MS methods specifically for afamelanotide in biological matrices, and the methodology published by Caubet et al. provides a useful framework for adapting these analytical approaches to pure compound QC work. 17

See our guide to reading peptide certificates of analysis for a step-by-step walkthrough of what each CoA parameter means and which failure modes to look for.

Dosage and Reconstitution

Reconstitution of the 10 mg vial

Lyophilized afamelanotide requires reconstitution with an aqueous solvent before use. Sterile water for injection (WFI) and 0.9% sodium chloride solution (normal saline) are both compatible; 0.1-1% acetic acid solutions are used in some protocols where solubility at low concentration is a concern, though the acetate salt form dissolves readily in water or saline in most practical scenarios. The peptide should not be exposed to vortex mixing; gentle swirling or inversion is sufficient. For full reconstitution guidance, see our guide to peptide reconstitution.

Worked example 1, stock solution for cell culture: A researcher wants a 1 mM stock solution from a 10 mg vial. Molecular weight = 1646.85 g/mol. 10 mg = 0.010 g. Moles = 0.010/1646.85 = 6.07 micromoles. To make 1 mM, volume required = 6.07 micromoles / 1 mmol/mL = 6.07 mL. Add 6.07 mL sterile WFI to the vial to obtain a 1 mM stock. This stock should be aliquoted into low-bind polypropylene tubes (50-200 microliters per aliquot) and stored at -80°C.

Worked example 2, 100 nM working concentration for melanocyte treatment: From the 1 mM stock above, prepare a 1:10,000 dilution in complete culture medium to reach 100 nM. Practically: dilute 1 microlitre of 1 mM stock into 9.999 mL medium, or use a two-step serial dilution (1 mM to 10 microM in 1:100 dilution, then 10 microM to 100 nM in 1:100 dilution) to minimize pipetting error. The in vitro studies reviewed above used concentrations of 10-100 nM, which correspond to plasma Cmax values achievable with literature-reported research doses in rodent models. 10

Worked example 3, rodent in vivo research dose calculation: Published rodent studies have used 0.1-1 mg/kg SC doses in mouse models of UV-induced pigmentation. For a 25 g mouse at 0.5 mg/kg: dose = 0.5 mg/kg x 0.025 kg = 0.0125 mg = 12.5 micrograms. From a 1 mM stock (1646.85 micrograms/mL): volume = 12.5 / 1646.85 x 1000 = 7.6 microliters. A practical injection volume for SC mouse dosing is 100-200 microliters; therefore dilute to an appropriate concentration in normal saline before injection. All animal protocols require institutional IACUC or equivalent ethical approval. For a detailed walkthrough of rodent dose calculations, see our dosage calculation guide.

Stability considerations

Reconstituted afamelanotide solutions are stable at 4°C for approximately 7 days in polypropylene tubes. Repeated freeze-thaw cycles degrade peptide integrity; single-use aliquots stored at -80°C are strongly preferred. The compound is sensitive to light (the Tyr and Trp residues absorb UV) and should be handled in amber or foil-wrapped tubes. At physiological pH (7.0-7.4) and temperature, the half-life for chemical degradation is substantially longer than for native alpha-MSH, primarily because the D-Phe7 substitution resists the chymotrypsin-like cleavage that would otherwise be the primary inactivation route in biological matrices.

Side Effects and Safety

Adverse effects documented in clinical trial literature

The adverse effect profile of afamelanotide in clinical trials is largely mild and manageable, which is one reason the compound received regulatory approval for EPP in the EU (2014), Australia (2016), and the United States (2019). The most frequently reported adverse events across multiple trials include transient nausea (incidence approximately 8-15% at 16 mg implant doses), implant-site reactions (erythema, induration, mild pain lasting 1-5 days), headache, fatigue, and hyperpigmentation of existing nevi. 1 Flushing is reported at higher bolus SC doses but is typically transient.

The spontaneous erection observed at higher bolus doses in the Fitzgerald 1996 trial was not replicated in subsequent implant trials, suggesting this may have been a Cmax-related off-target effect at MC4R rather than a sustained effect of the compound at therapeutic exposure levels. At the sustained low plasma concentrations maintained by the implant formulation, central side effects appear absent or below the threshold of detection.

Melanoma and proliferation risk

The theoretical concern with any chronically administered MC1R agonist is promotion of melanocytic proliferation. The published long-term safety data, covering more than 1000 patient-years of implant treatment in EPP cohorts, does not show a melanoma signal, and mechanistic arguments from eumelanin's photoprotective and ROS-scavenging properties make a pro-carcinogenic effect unlikely at therapeutic exposures. 5 However, researchers working with immortalized melanocyte lines or melanoma cell lines should directly assess proliferation endpoints (MTT, Ki-67 immunostaining) in their specific experimental system rather than assuming general safety conclusions from clinical patient cohorts apply to their model.

Cardiovascular and metabolic safety

Cardiovascular effects of afamelanotide appear absent at clinical doses. Blood pressure, heart rate, and ECG parameters have been monitored in clinical trials without detected abnormalities attributable to the compound. 1 MC1R is expressed in vascular endothelium and some data suggest vasodilatory effects at very high concentrations in isolated vessel preparations, but this has not translated to clinically observed hemodynamic changes at therapeutic plasma concentrations.

No metabolic (glycemic, lipid) effects have been documented in EPP trial populations. MC4R mediates metabolic melanocortin signaling; afamelanotide's low MC4R efficacy means it does not replicate the energy homeostasis effects seen with non-selective melanocortin agonists.

Safety in immunocompromised research models

Researchers using afamelanotide in immunocompromised animal models (nude mice, SCID mice, TALEN knockouts) should be aware that the compound's anti-inflammatory NF-kB-inhibitory effects may alter immune-surveillance biology in ways not reflected in clinical trial data from immunocompetent EPP patients. This is not a specific documented toxicity but a gap in the literature that researchers should factor into experimental design.

How It Compares

The melanocortin peptide research space includes several related compounds. Understanding how afamelanotide relates to these alternatives helps researchers select the appropriate tool for their specific research question.

The most important comparison for most researchers is between Melanotan-1 and Melanotan-II. Both are alpha-MSH analogs with the Nle4 and D-Phe7 substitutions (Melanotan-II uses a cyclized version of the core pharmacophore), but Melanotan-II's cyclic lactam bridge additionally constrains the peptide into a conformation with enhanced MC4R binding. 2 For any research question related specifically to skin pigmentation, photoprotection, or MC1R biology, Melanotan-1 is the preferred tool because its effects can be attributed to MC1R with greater confidence. For research into sexual function, appetite regulation, or MC4R-dependent signaling, Melanotan-II or setmelanotide would be more appropriate.

The comparison with endogenous alpha-MSH is also instructive. Alpha-MSH has the same receptor binding sequence but is rapidly degraded in solution; it is useful as a short-duration acute stimulation control but impractical for sustained or time-course studies. Afamelanotide's resistance to peptidase cleavage makes it more suitable for studies requiring stable peptide concentrations over multi-hour or multi-day periods without continuous replenishment.

NDP-alpha-MSH is widely used as the reference radioligand competitor in MC receptor binding assays. Afamelanotide's binding affinity relative to NDP-alpha-MSH has been measured in competitive displacement assays; while both bind MC1R with high affinity, NDP-alpha-MSH shows marginally higher affinity in most published assays. For research applications other than pure binding assay work, this difference is unlikely to matter. 8

Where to Buy

Apollo Peptide Sciences supplies this product through their research catalog; see our complete Melanotan-1 Acetate 10mg review page for the current pricing, batch availability, and CoA access details. The product page handles the outbound vendor link; we do not link directly to affiliate URLs within editorial content.

When evaluating any research peptide supplier, the minimum acceptable quality indicators are: a publicly accessible or request-available CoA with batch-specific HPLC purity data and mass spec confirmation, a documented synthesis date and shelf life, clear storage instructions, and a responsive technical support team. For a broader evaluation framework covering how to assess peptide vendor quality, third-party testing options, and red flags to watch for, see our comprehensive supplier selection guide.

Open Research Questions

The afamelanotide literature is relatively mature compared with many research peptides, but several areas remain genuinely contested or underexplored.

Quantitative MC1R subtype selectivity: Despite decades of research, precise Ki values for afamelanotide at each of the five melanocortin receptor subtypes are not uniformly published, and values from different assay systems (radioligand competition, calcium flux, cAMP accumulation) are not always concordant. The functional relevance of partial MC3R or MC4R engagement at the plasma concentrations achieved by high bolus doses remains an open question.

Photocarcinogenesis in long-term models: The clinical trial safety data does not rule out small increases in melanoma risk over very long exposure periods. Transgenic mouse models of UV-induced melanoma, treated chronically with afamelanotide, could provide pre-clinical data that would either reinforce or challenge the current optimistic safety picture. As of 2025, no such study has been published.

Non-skin tissue MC1R biology: The expression of MC1R in the kidney, muscle, and CNS suggests potential pharmacological effects in those tissues, but systematic studies of afamelanotide's effects in these compartments at relevant concentrations remain sparse. The renal podocyte data is intriguing but limited to a small number of publications. 12

Combination with photosensitizing agents: EPP management sometimes involves multiple interventions. The interaction between afamelanotide's MC1R agonism and photosensitizing agents or photodynamic therapy agents has not been systematically examined. This is a practical gap given the increasing clinical interest in photodynamic therapy for skin cancer.

Biomarker development: No validated pharmacodynamic biomarker exists for real-time MC1R engagement in vivo (as opposed to the downstream surrogate of skin colorimetry). Development of such a biomarker would accelerate dose-optimization research and improve translation between preclinical and clinical studies.